Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
You may also be interested in...
If pharma got to choose, it would pick the bills that seek to discourage price increases instead of the ones that allow the government to negotiate drug prices or use international reference pricing. It is unclear whether any legislation will pass, but without a Republican majority in the Senate, the risk for industry has never been greater.
Senate Finance confirmation hearing concluded without a vote on Xavier Becerra’s nomination as Health and Human Services Department secretary. Republicans continued to express concerns with his background and views. But he is expected to win enough votes to clear the committee.
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.